Abstract
Importance Amyotrophic lateral sclerosis (ALS) is a multi-system disorder characterized primarily by motor neuron degeneration, but may be accompanied by cognitive dysfunction. Statistically appropriate criteria for establishing cognitive impairment (CI) in ALS are lacking.
Objective Define thresholds for CI in ALS using quantile regression (QR) that accounts for age and education in a North American (NAmer) cohort.
Design QR of cross-sectional data from a multi-center NAmer cohort of healthy adults was used to model the 5th percentile of cognitive scores on the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). The QR approach was compared to a traditional 2 standard deviation (SD) cut-off approach using the same NAmer cohort (2SD-NAmer) and to existing UK-based normative data derived using the 2SD approach (2SD-UK) to assess the impact of cohort selection and statistical model in identifying CI ALS patients.
Participants 269 healthy adults from NAmer, recruited by the University of Pennsylvania (PENN; N=82), the University of Miami through the CRiALS study (CRiALS; N=40), and the Canadian ALS Neuroimaging Consortium (CALSNIC; N=147) were included to establish ECAS thresholds for defining CI. We then evaluated the frequency of CI in 182 ALS patients from PENN.
Main Outcomes We defined two new sets of normative thresholds, based on NAmer heathy adult performance, for each ECAS domain score and the composite scores using QR and 2SD statistical approaches. We then applied the 2SD-NAmer and QR-NAmer, as well as the previously established and widely-used 2SD-UK, thresholds to evaluate the frequency of CI in ALS patients.
Results QR-NAmer models revealed that increased age and reduced educational attainment negatively impact cognitive performance on the ECAS. Based on the QR-NAmer normative cutoffs, the prevalence of CI in the 182 PENN ALS patients was 15.9% for ECAS ALS-Specific and 15.4% for ECAS Total. These estimates are more conservative than estimates ranging from 15.4%-34.6% impaired based on 2SD approaches.
Conclusions and Relevance This report establishes normative thresholds for using ECAS to identify whether ALS patients in the NAmer population have CI. The choice of statistical method and normative cohort has a substantial impact on defining CI in ALS.
Question How to define cognitive impairment (CI) in amyotrophic lateral sclerosis (ALS) using the Edinburgh Cognitive and Behavioral ALS Screen (ECAS)?
Findings Age- and education-adjusted quantile regression (QR) yields thresholds for defining CI that differ meaningfully from those derived from parametric methods without age- and education-adjustment. Thresholds also differ between UK and North American cohorts. Applying our North American-based QR norms to an American ALS cohort at a single center identified CI based on ECAS performance in ∼16% patients, compared to 15.4%-34.6% patients using other approaches.
Meaning The choice of statistical method and normative cohort has a substantial impact on defining CI in ALS.
Competing Interest Statement
Dr. McMillan reports grants from the National Institutes of Health (NIH; AG017586; AG066597). Dr. Kalra reports grants that support CALSNIC including the Canadian Institutes of Health Research, ALS Society of Canada, Brain Canada Foundation, and Shelly Mrkonjic ALS Research Fund. Dr. Benatar reports grants from Muscular Dystrophy Association (Grants #4365 and #172123), the ALS Association (Grant #2015), and the National Institutes of Health (NIH; NS105479); philanthropic support from the ALS Recovery Fund and the Kimmelman Estate during the conduct of the study; Dr. McMillan receives research funding outside the submitted work from Biogen, Inc and provides consulting services for personal fees from Invicro and Axon Advisors on behalf of Translational Bioinformatics, LLC. He also receives an honorarium as Associate Editor of NeuroImage: Clinical. Dr. Johnston receives research funding from Annexon, Alexion, ALS-Pharma, Biogen, Cytokinetics, Mallinckrodt, Mitsubishi-Tanabe Canada, Orion, and serves as a paid consultant to Biogen and Mitsubishi-Tanabe Canada. Dr. Genge provides consulting services for the following companies: AB Sciences, Akcea, Alexion, AL-S Pharma, Anavex, Avexis, Bayshore, Biogen, Clene, CSL Behring, Cytokinetics, QurAlis, Mitsubishi Tenabe Pharma America, Novartis, Orion, Revalesio, Roche, Sanofi Genzyme, and Wave life sciences. She is also CRU Medical Director, PI or sub-PI on trials sponsored by the following companies: AB Sciences, AL-S Pharma, Acceleron, Amicus, Alnylam, Bioblast, Biogen, BMS, Boston Biomedical, Cytokinetics, Sanofi Genzyme, Grifols, Ionis, Lily, Mallinckrodt, Medimmune, Novartis, Orion, Orphazyme, Pfizer, Ra Pharmaceuticals, Roche, Teva, and UCB. Dr. Benatar reports personal fees from Roche and Biogen. Drs. Wuu, Rascovsky, Cosentino, Grossman, Elman, Quinn, Rosario, Stark, Granit, Briemberg, Chenji, Dionne, Korngut, Shoesmith, Zinman report no conflicts of interest.
Funding Statement
Dr. McMillan reports grants from the National Institutes of Health (NIH; AG017586; AG066597). Dr. Kalra reports grants that support CALSNIC including the Canadian Institutes of Health Research, ALS Society of Canada, Brain Canada Foundation, and Shelly Mrkonjic ALS Research Fund. Dr. Benatar reports grants from Muscular Dystrophy Association (Grants #4365 and #172123), the ALS Association (Grant #2015), and the National Institutes of Health (NIH; NS105479); philanthropic support from the ALS Recovery Fund and the Kimmelman Estate during the conduct of the study;
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PENN research protocol was approved by an Institutional Review Board convened at the University of Pennsylvania and all participants provided written consent following an approved informed consent procedure... The CRiALS research protocol was approved by an Institutional Review Board convened at the University of Miami and all participants provided written consent following an approved informed consent procedure... The CALSNIC research protocol was approved by a Health Research Ethics Board convened at each of the participating universities including University of Alberta, University of British Columbia, Universite Laval, University of Calgary, the Montreal Neurological Institute and Hospital at McGill University, Western University, and University of Toronto. All participants at each of these institutions provided written consent following an approved informed consent procedure.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data may be provided to outside investigators pending review of reasonable requests.